A complement C1q detection kit and preparation method thereof

By adding lipoprotein esterase and emulsifier to the complement C1q detection kit to eliminate lipid blood interference, and using HEPES buffer and complement C1q antibody for specific binding, the complex detection, low accuracy and interference in the prior art are solved. Sensitive problems achieve fast and accurate complement C1q detection.

CN115825445BActive Publication Date: 2024-11-26ANHUI IPROCOM BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211183032.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-09-27
Publication Date
2024-11-26
Estimated Expiration
2042-09-27

AI Technical Summary

Technical Problem

The existing complement C1q detection methods have problems such as complex operation, low accuracy, poor repeatability and sensitivity to lipid blood interference. In particular, the detection of enzyme-linked immunosorbent assay takes a long time and the results are greatly affected by human factors, making it difficult to automate.

Method used

Provide a complement C1q detection kit, which eliminates lipid blood interference by adding lipoprotein esterase and emulsifier to reagent R1, and uses HEPES buffer and complement C1q antibody in reagent R2 to achieve specific binding, and calculates the sample. Complement C1q content.

Benefits of technology

It realizes fast, accurate, and strong anti-interference ability complement C1q detection, which is suitable for fully automatic large-scale inspection, improves the stability and linear range of reagents, and ensures the stability and accuracy of the detection results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115825445B_ABST
    Figure CN115825445B_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of complement C1q detection kits, and discloses a complement C1q detection kit and a preparation method thereof. The kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 comprises sodium dihydrogen phosphate, dipotassium hydrogen phosphate, an emulsifier, DTPA, sodium chloride, polyethylene glycol, lipoprotein lipase, Tween and a blocking agent; and the reagent R2 comprises HEPES, sodium chloride, sodium azide, polyethylene glycol and a complement C1q antibody. The complement C1q detection kit of the invention is suitable for complement C1q detection on a biochemical analyzer, which not only improves reagent stability and reagent linearity, but also improves the anti-interference ability and accuracy of the detection of the kit, and provides a product selection with better stability, wider linear range, stronger anti-interference ability and higher accuracy for clinical medical examinations.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of complement C1q detection kits, in particular to a complement C1q detection kit and a preparation method thereof. Background Art

[0002] Complement C1 is a multimeric molecular complex composed of 6 subunits, of which C1q is one of the subunits. C1q, C1r and C1s form the C1 complex in a ratio of 1:2:2. It is the first component of the classical complement pathway. C1q is composed of 18 polypeptide chains (six A, six B, and six C) (MW 460kDa) and a total of 6 subunits. Each subunit contains a collagen-like sequence at the N-terminus and a globular structure at the C-terminus. They all contain an 81-aa collagen-like region composed of a (Gly-Xaa-Yaa) repeating sequence near the N-terminus. Complement C1q has become an important tool for clinical diagnosis, disease monitoring and condition observation. With further in-depth research, complement C1q will have greater clinical significance and broader clinical application prospects in disease prevention and treatment.

[0003] Currently, the detection methods of serum complement C1q include one-way immunodiffusion, immunoturbidimetry and enzyme-linked immunosorbent assay.

[0004] Among them, the one-way immunodiffusion method is a traditional and outdated method. It is affected by many factors and has defects such as complex operation and low accuracy, so its clinical application is limited. The enzyme-linked immunosorbent assay has complicated operation steps and the detection time is more than 90 minutes. The results are greatly affected by human operation factors, especially temperature and time factors. The results have a great influence on the results, the repeatability is poor, and it is difficult to automate.

[0005] Immunoturbidimetry is currently the method most commonly used in clinical practice. Immunoturbidimetry is an antigen-antibody specific binding reaction. It quantifies the turbidity changes produced by the antigen-antibody immune complex formed by the detection reaction. It utilizes the specific binding between antigen and antibody and has the advantages of good stability, simple and convenient operation, rapid detection, good repeatability, high accuracy, and no pollution. It is used in automatic biochemical analyzers. Currently, immunoturbidimetry has been widely used in the detection of apolipoprotein B, prealbumin, fibronectin, etc., which has brought good news to patients and created huge social benefits.

[0006] However, since lipemia samples containing chylomicrons are milky white and turbid, they will affect the absorbance of many biochemical reactions and the change of product color, and significantly interfere with the biochemical results detected by turbidimetry and colorimetry. Therefore, there is an urgent need in the art for a kit for detecting complement C1q that can overcome the interference of lipemia. Summary of the invention

[0007] The present invention provides a kit suitable for measuring complement C1q with a biochemical analyzer. The detection time is 10 minutes and the kit is suitable for fully automatic large-scale detection. The complement C1q detection kit of the present invention not only improves reagent stability and reagent linearity, but also improves the anti-interference ability and accuracy of the kit detection, and provides a product selection with better stability, wider linear range, stronger anti-interference ability and higher accuracy for clinical medical examination.

[0008] To achieve the above object, the present invention provides the following technical solutions:

[0009] In a first aspect, the present invention provides a complement C1q detection kit, the complement C1q detection kit comprising a reagent R1 and a reagent R2;

[0010] Wherein, reagent R1 comprises: lipoprotein lipase 0.5-5KU / L, emulsifier 0.1-10g / L, blocking agent 1-100mg / L, sodium dihydrogen phosphate 5.0-50.0g / L, dipotassium hydrogen phosphate 5.0-50.0g / L, diethylenetriamine pentaacetic acid 0.2-2.0g / L, sodium chloride 5-50g / L, polyethylene glycol 5-50g / L, Tween 0.2-2.0g / L, and the solvent is purified water;

[0011] Reagent R2 includes: complement C1q antibody 50-500 ml / L, 4-hydroxyethylpiperazineethanesulfonic acid (HEPES) 5-500 mmol / L, sodium chloride 5-50 g / L, sodium azide 0.5-5 g / L, polyethylene glycol 5-50 g / L, and the solvent is purified water.

[0012] In the present invention, the reaction principle of the complement C1q detection kit is: the complement C1q in the body fluid sample can produce a specific antigen-antibody binding reaction with the complement C1q antibody in the reagent to form an antigen-antibody immune complex, and its turbidity changes. At a specific wavelength, the content of complement C1q in the sample is proportional to the turbidity formed by it, and the content of complement C1q in the sample is calculated. Among them, by adding lipoprotein esterase and emulsifier to reagent R1, lipoprotein esterase hydrolyzes triglycerides in the lipemia sample to generate colorless, water-soluble and non-antigenic glycerol and fatty acids, and the emulsifier is adsorbed on the oil phase / water phase interface of the lipemia sample, which plays a role in reducing interfacial tension and protecting glycerol and fatty acid droplets from aggregation, thereby ensuring the stability of the sample and reagent reaction system, and through the synergistic effect between lipoprotein esterase and emulsifier, a good technical effect of eliminating lipemia interference is achieved.

[0013] Among them, the content of lipoprotein lipase in reagent R1 is 0.5-5KU / L, for example, it can be 0.5KU / L, 0.8KU / L, 1KU / L, 1.2KU / L, 1.5KU / L, 2KU / L, 2.5KU / L, 3KU / L, 4KU / L or 5KU / L, etc.

[0014] The content of emulsifier in reagent R1 is 0.1-10g / L, for example, it can be 0.1g / L, 0.5g / L, 1g / L, 1.5g / L, 2g / L, 2.5g / L, 3g / L, 3.5g / L, 4g / L, 4.5g / L, 5g / L, 5.5g / L, 6g / L, 6.5g / L, 7g / L, 7.5g / L, 8g / L, 8.5g / L, 9g / L, 9.5g / L or 10g / L, etc.

[0015] The content of the blocking agent in reagent R1 is 1-100 mg / L, for example, it can be 1 mg / L, 2 mg / L, 5 mg / L, 10 mg / L, 15 mg / L, 20 mg / L, 25 mg / L, 30 mg / L, 35 mg / L, 40 mg / L, 45 mg / L, 50 mg / L, 55 mg / L, 60 mg / L, 65 mg / L, 70 mg / L, 75 mg / L, 80 mg / L, 85 mg / L, 90 mg / L, 95 mg / L, or 100 mg / L, etc.

[0016] The content of sodium dihydrogen phosphate in reagent R1 is 5.0-50.0 g / L, for example, it can be 5.0 g / L, 10 g / L, 15 g / L, 20 g / L, 25 g / L, 30 g / L, 35 g / L, 40 g / L, 45 g / L or 50 g / L.

[0017] The content of dipotassium hydrogen phosphate in reagent R1 is 5.0-50.0 g / L, for example, it can be 5.0 g / L, 10 g / L, 15 g / L, 20 g / L, 25 g / L, 30 g / L, 35 g / L, 40 g / L, 45 g / L or 50 g / L.

[0018] The content of diethylenetriaminepentaacetic acid in reagent R1 is 0.2-2.0 g / L, for example, it can be 0.2 g / L, 0.4 g / L, 0.5 g / L, 0.6 g / L, 0.8 g / L, 1 g / L, 1.2 g / L, 1.5 g / L, 1.8 g / L or 2 g / L, etc.

[0019] The content of sodium chloride in reagent R1 is 5-50 g / L, for example, it can be 5.0 g / L, 10 g / L, 15 g / L, 20 g / L, 25 g / L, 30 g / L, 35 g / L, 40 g / L, 45 g / L or 50 g / L, etc.

[0020] The content of polyethylene glycol in reagent R1 is 5-50 g / L, for example, it can be 5.0 g / L, 10 g / L, 15 g / L, 20 g / L, 25 g / L, 30 g / L, 35 g / L, 40 g / L, 45 g / L or 50 g / L, etc.

[0021] The content of Tween in reagent R1 is 0.2-2.0 g / L, for example, it can be 0.2 g / L, 0.4 g / L, 0.5 g / L, 0.6 g / L, 0.8 g / L, 1 g / L, 1.2 g / L, 1.5 g / L, 1.8 g / L or 2 g / L, etc.

[0022] The content of complement C1q antibody in reagent R2 is 50-500 ml / L, for example, it can be 50 ml / L, 80 ml / L, 100 ml / L, 150 ml / L, 200 ml / L, 250 ml / L, 280 ml / L, 300 ml / L, 350 ml / L, 400 ml / L, 450 ml / L or 500 ml / L.

[0023] The content of 4-hydroxyethylpiperazineethanesulfonic acid (HEPES) in reagent R2 is 5-500mmol / L, for example, it can be 5mmol / L, 10mmol / L, 50mmol / L, 100mmol / L, 150mmol / L, 200mmol / L, 250mmol / L, 300mmol / L, 350mmol / L, 400mmol / L, 450mmol / L or 500mmol / L, etc.

[0024] The content of sodium chloride in reagent R2 is 5-50g / L, for example, it can be 5.0g / L, 10g / L, 15g / L, 20g / L, 25g / L, 30g / L, 35g / L, 40g / L, 45g / L or 50g / L, etc.

[0025] The content of sodium azide in reagent R2 is 0.5-5 g / L, for example, it can be 0.5 g / L, 1 g / L, 1.5 g / L, 2 g / L, 2.5 g / L, 3 g / L, 3.5 g / L, 4 g / L, 4.5 g / L or 5 g / L, etc.

[0026] The content of polyethylene glycol in reagent R2 is 5-50 g / L, for example, it can be 5.0 g / L, 10 g / L, 15 g / L, 20 g / L, 25 g / L, 30 g / L, 35 g / L, 40 g / L, 45 g / L or 50 g / L, etc.

[0027] As a preferred technical solution of the present invention, the lipoprotein esterase is lipoprotein lipase (LPL).

[0028] Preferably, the emulsifier is bovine serum albumin (BSA).

[0029] The present invention adds lipoprotein lipase (LPL) and bovine serum albumin (BSA) to the reagent R1, and the LPL and BSA act synergistically, and LPL and BSA are indispensable, and BSA cannot be replaced by other emulsifiers; the two cooperate to make the triglyceride in the lipemia sample generate colorless, water-soluble and non-antigenic glycerol and fatty acids, and BSA is adsorbed on the oil phase / water phase interface of the lipemia sample, which plays a role in reducing interfacial tension and protecting glycerol and fatty acid droplets from aggregation, thereby enhancing the physical stability of sample detection, ensuring the stability of the sample and reagent reaction system, and achieving a good technical effect of eliminating lipemia interference.

[0030] Preferably, the blocking agent is an IgG-Fc fragment.

[0031] In the present invention, the IgG-Fc fragment can be an IgG-Fc fragment formed after the denatured IgG antibody is hydrolyzed by papain. The IgG-Fc fragment is added to the reagent R1, and the IgG-Fc fragment specifically binds to the rheumatoid factor in the sample, thereby avoiding the non-specific binding of the rheumatoid factor and the complement C1q antibody to cause a false positive. Rheumatoid factor is derived from the antigenic determinant cluster of the Fc fragment of the human IgG molecule, and is a class of antibodies with denatured IgG as the target antigen. The denatured IgG antibody is hydrolyzed into an IgG-Fc fragment by papain, and the obtained IgG-Fc fragment is added to the reagent R1. The rheumatoid factor in the sample can specifically bind to the IgG-Fc fragment in the reagent R1, thereby avoiding the non-specific binding of the rheumatoid factor and the complement C1q antibody to cause a false positive.

[0032] As a preferred technical solution of the present invention, the polyethylene glycol in the reagent R1 is PEG-8000.

[0033] Preferably, the Tween in the reagent R1 is Tween-40.

[0034] In the present invention, the polyethylene glycol and Tween with the above molecular weight are selected to help improve the stability of the reagent.

[0035] As a preferred technical solution of the present invention, the pH of the reagent R1 is 5.0-9.0, for example, it can be 5.0, 5.5, 6.0, 6.5, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 8.0, 8.5 or 9.0, etc., preferably 7.0-7.4;

[0036] Preferably, the pH of the reagent R2 is 5.0-9.0, for example, it can be 5.0, 5.5, 6.0, 6.5, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 8.0, 8.5 or 9.0, etc., preferably 7.0-7.4.

[0037] As a preferred technical solution of the present invention, the reagent R1 comprises: lipoprotein lipase 2-3KU / L, bovine serum albumin 0.1-2g / L, IgG-Fc fragment 10-30mg / L, diethylenetriaminepentaacetic acid 0.2-0.8g / L, sodium dihydrogen phosphate 20-30g / L, dipotassium hydrogen phosphate 20-50g / L, sodium chloride 5-20g / L, PEG-8000 30-40g / L, Tween-40 0.2-1g / L, pH 7.0-7.4; the solvent is purified water;

[0038] The components and corresponding contents of the reagent R2 are: complement C1q antibody 100-300 ml / L, 4-hydroxyethylpiperazineethanesulfonic acid 100-300 mmol / L; sodium chloride 5-20 g / L; sodium azide 1 g / L, PEG-8000 30-40 g / L, pH 7.0-7.4; and the solvent is purified water.

[0039] As a preferred technical solution of the present invention, the reagent R1 comprises: lipoprotein lipase 2.5KU / L, bovine serum albumin 0.5g / L, IgG-Fc fragment 20mg / L, diethylenetriaminepentaacetic acid 0.5g / L, sodium dihydrogen phosphate 27.0g / L, dipotassium hydrogen phosphate 28.6g / L, sodium chloride 9g / L, PEG-8000 35g / L, Tween-40 0.7g / L, pH 7.0-7.4; the solvent is purified water;

[0040] The components and corresponding contents of the reagent R2 are: complement C1q antibody 200 ml / L, 4-hydroxyethylpiperazineethanesulfonic acid 200 mmol / L; sodium chloride 15 g / L; sodium azide 1 g / L, PEG-8000 35 g / L, pH 7.0-7.4; and the solvent is purified water.

[0041] On the other hand, the present invention also provides a method for preparing a complement C1q detection kit, the preparation method comprising the following steps:

[0042] Preparation of reagent R1: dissolving a formulated amount of sodium dihydrogen phosphate in purified water, and then sequentially adding dipotassium hydrogen phosphate, diethylenetriamine pentaacetic acid and sodium chloride to obtain reagent R1 buffer; then, dissolving Tween, polyethylene glycol and a blocking agent in the reagent R1 buffer in sequence, and then adding an emulsifier, adjusting the pH, and adding a blocking agent and lipoprotein lipase LPL to obtain the reagent R1;

[0043] Preparation of reagent R2: dissolve the formulated amount of 4-hydroxyethylpiperazineethanesulfonic acid in purified water, and then add sodium chloride, sodium azide and polyethylene glycol in sequence to obtain the reagent R2 storage solution; then, add complement C1q antibody, stir until completely dissolved, let stand, filter and sterilize to obtain the reagent R2.

[0044] As a preferred technical solution of the present invention, the standing time is 5 to 8 days, for example, 5 days, 6 days, 7 days, 7.5 days or 8 days, preferably 7 days.

[0045] Preferably, the standing temperature is 2-8°C, for example, 2°C, 3°C, 4°C, 5°C, 6°C, 7°C or 8°C.

[0046] In a third aspect, the present invention provides a method for using the complement C1q detection kit of the first aspect in non-disease diagnosis, wherein the complement C1q detection kit is used in conjunction with a biochemical analyzer, and the specific steps include:

[0047] After the sample to be tested is mixed with reagent R1 and reagent R2 for reaction, the absorbance of the solution is detected, and the concentration of complement C1q in the sample to be tested is obtained according to the change in the absorbance.

[0048] In the present invention, the complement C1q detection kit is used to detect the concentration of complement C1q, and the results obtained can be used for the diagnosis of diseases. In addition, when the detection object is derived from non-human animals, such as mice, rats, rabbits, monkeys, etc., the results obtained can be used for scientific research and discovery. That is to say, the complement C1q detection kit of the present invention can be used not only for the diagnosis and treatment of diseases, but also for the diagnosis and treatment of non-diseases.

[0049] In the present invention, the reaction principle of the complement C1q detection kit is: the complement C1q in the body fluid sample can produce a specific antigen-antibody binding reaction with the complement C1q antibody in the reagent to form an antigen-antibody immune complex, the turbidity of which changes. At a specific wavelength, the content of complement C1q in the sample is proportional to the turbidity formed, and the content of complement C1q in the sample is calculated, and the calculation formula is as follows:

[0050]

[0051] Where: ΔA T It indicates the absorbance change value of the sample tube compared with the blank tube;

[0052] ΔA S It indicates the absorbance change of the calibration tube compared with the blank tube;

[0053] C S represents the concentration of complement C1q in the calibration solution;

[0054] C C1q Indicates the concentration of complement C1q in the sample;

[0055] Compared with the prior art, the present invention has the following beneficial technical effects:

[0056] (1) The present invention adds lipoprotein lipase and emulsifier to reagent R1. Lipoprotein lipase hydrolyzes triglycerides in lipemia samples to generate colorless, water-soluble and non-antigenic glycerol and fatty acids, while the emulsifier is adsorbed on the oil phase / water phase interface of the lipemia sample to reduce interfacial tension and protect glycerol and fatty acid droplets from aggregation, thereby enhancing the physical stability of sample detection and ensuring the stability of the sample and reagent reaction system. Through the synergistic effect between lipoprotein lipase and emulsifier, a good technical effect of eliminating lipemia interference is achieved. When the blood lipid concentration is less than 2000 mg / dL, there will be no obvious interference;

[0057] (2) The present invention hydrolyzes the denatured IgG antibody into IgG-Fc fragments by papain, and then adds the obtained IgG-Fc fragments to reagent R1. The rheumatoid factor in the sample can specifically bind to the IgG-Fc fragment in reagent R1, thereby avoiding the non-specific binding of rheumatoid factor and complement C1q antibody to cause false positive test results;

[0058] (3) When the present invention uses HEPES buffer as the storage solution in R2, it can maintain a stable trend under various conditions, with the best stability, and the upper limit of the linear range can reach more than 70 mg / dL, and the linear correlation coefficient R 2 Reach 0.99; at the same time, the present invention also prevents the non-specific binding of low-affinity immune complexes in serum to C1q by adding sodium chloride salt to the buffer, that is, avoids self-reaction and ensures the accuracy of the complement C1q detection kit; therefore, the present invention improves the anti-interference ability of the kit detection while also improving the stability, linearity and accuracy of the reagent. BRIEF DESCRIPTION OF THE DRAWINGS

[0059] Figure 1 is a linear relationship diagram between the measured value and the expected value of the R2 reagent prepared by HEPES buffer;

[0060] Figure 2 It is a linear relationship diagram between the measured value and the expected value of the R2 reagent prepared by PBS buffer;

[0061] Figure 3 is a linear relationship diagram of the measured value and the expected value of the R2 reagent prepared by TRIS buffer;

[0062] Figure 4 is a linear relationship diagram between the measured value and the expected value of the R2 reagent prepared by PIPES buffer;

[0063] Figure 5 is a linear relationship diagram of the measured value and the expected value of the R2 reagent prepared from acetate buffer;

[0064] Figure 6 is a linear relationship diagram between the measured value and the expected value of the R2 reagent prepared from MOPS buffer;

[0065] Figure 7 It is a linear relationship diagram between the measured value of adding sodium chloride to the R2 reagent and the sample value measured by the comparison method;

[0066] Figure 8 This is a linear relationship diagram between the measured value without adding sodium chloride to the R2 reagent and the sample value measured by the comparison method. DETAILED DESCRIPTION

[0067] The technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments. In the absence of conflict, the embodiments in this application and the features in the embodiments can be combined with each other. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work belong to the scope of protection of the present invention.

[0068] The reagents used in the following examples can all be purchased from conventional manufacturers in the field; the experimental methods used are all conventional experimental methods known to those skilled in the art.

[0069] Example 1

[0070] The present invention provides a complement C1q detection kit, comprising:

[0071] (1) The composition and corresponding content of the application liquid-reagent R1 are:

[0072] Lipoprotein lipase (LPL), 2.5KU / L; BSA, 0.5g / L; IgG-Fc fragment, 20mg / L; sodium dihydrogen phosphate, 27.0g / L; potassium dihydrogen phosphate, 28.6g / L; diethylenetriaminepentaacetic acid (DTPA), 0.5g / L; sodium chloride, 9g / L; PEG-8000, 35g / L; Tween-40, 0.7g / L; pH is 7.2; the solvent is purified water;

[0073] (2) The components and corresponding contents of the complement C1q antibody solution-reagent R2 are:

[0074] 4-Hydroxyethylpiperazineethanesulfonic acid (HEPES), 200mmol / L; sodium chloride, 15g / L; sodium azide, 1g / L; polyethylene glycol PEG-8000, 35g / L; complement C1q antibody, 200ml / L; pH is 7.2; the solvent is purified water;

[0075] Example 2

[0076] This embodiment provides a method for using a complement C1q detection kit, which specifically includes:

[0077] (1) Complement C1q detection kit provided in Example 1 was used to perform complement C1q detection on a biochemical analyzer. The specific test parameters were as follows:

[0078] 1. Reaction temperature: 37°C;

[0079] 2. Analytical method: endpoint method;

[0080] 3. Main wavelength: 340nm; sub-wavelength: 700nm;

[0081] 4. Sample volume / application solution (R1) / complement C1q antibody solution (R2): 4 μL / / 240 μL / 60 μL;

[0082] 5. Reaction direction: rising;

[0083] (2) When the complement C1q detection kit provided in Example 1 is used for detection on a biochemical analyzer, the specific operating parameters are shown in Table 1 below;

[0084] Table 1

[0085]

[0086] The reaction principle of the complement C1q detection kit is: the complement C1q in the body fluid sample can produce a specific antigen-antibody binding reaction with the complement C1q antibody in the reagent to form an antigen-antibody immune complex, and its turbidity changes. At a wavelength of 340nm, the content of complement C1q in the sample is proportional to the turbidity formed, and the content of complement C1q in the sample is calculated from it. The calculation formula is as follows:

[0087]

[0088] Where: ΔA T Indicates the absorbance change of the sample tube compared with the blank tube; ΔA S Indicates the absorbance change of the calibration tube compared with the blank tube; C S represents the concentration of complement C1q in the calibration solution; C C1q Indicates the concentration of complement C1q in the sample.

[0089] Example 3

[0090] Since lipemia samples containing chylomicrons are milky white and turbid, they will affect the absorbance of many biochemical reactions and changes in product color, and significantly interfere with the biochemical results detected by turbidimetry and colorimetry.

[0091] In order to eliminate the interference of lipemia, the present invention implements the following experimental scheme to eliminate the interference, specifically:

[0092] (1) Comparative Example 1: Compared with Example 1, the only difference is that the kit does not contain lipoprotein lipase and bovine serum albumin;

[0093] (2) Comparative Example 2: Compared with Example 1, the only difference is that only lipoprotein lipase is added to the kit, and its concentration is increased to 5 KU / L;

[0094] (3) Comparative Example 3: Compared with Example 1, the only difference is that only bovine serum albumin is added to the kit, and its concentration is increased to 1 g / L;

[0095] (4) Using Example 1, i.e., comprising lipoprotein lipase LPL and bovine serum albumin BSA;

[0096] Samples containing different blood lipid concentrations were tested, and the effect of the reagent in eliminating blood lipid interference was evaluated based on the relative deviation. The test results are shown in Table 2 below;

[0097] Table 2

[0098]

[0099]

[0100] As shown in Table 2 , (1) without LPL and BSA: when the blood lipid concentration is greater than 750 mg / dL, there is interference;

[0101] (2) Only LPL is added: There is interference when the blood lipid concentration is greater than 1250 mg / dL;

[0102] (3) Only adding BSA: There is interference when the blood lipid concentration is greater than 1250 mg / dL;

[0103] (4) Adding LPL and BSA at the same time: When the blood lipid concentration is greater than 2000 mg / dL, there may be interference.

[0104] The present invention achieves a good technical effect of eliminating lipidemia interference through the synergistic effect between lipoprotein lipase LPL and bovine serum albumin BSA.

[0105] Example 4

[0106] In order to improve the stability of reagent R2, the following experimental scheme was implemented, specifically: 6 different buffers (including HEPES buffer, PBS buffer, TRIS buffer, PIPES buffer, acetate buffer and MOPS buffer) were prepared to prepare 6 different R2 reagents respectively;

[0107] Under the conditions of 37°C acceleration and 4°C refrigeration, the test results of the reagents at different times were monitored, and the test results are shown in Table 3 below;

[0108] Table 3

[0109]

[0110]

[0111]

[0112]

[0113] As shown in Table 3, HEPES buffer: when stored at 4°C for 1 year and 1.5 years, the deviations of OD2-OD5, Px, Py, and serum H / L were all <10.0%;

[0114] PBS buffer: when stored at 4℃ for 1 year, the deviations of OD2, OD3, and Py are greater than 10%; when stored at 4℃ for 1.5 years, the deviations of OD2, OD3, OD4, OD5, and Py are all greater than 10.0%;

[0115] TRIS buffer: when stored at 4℃ for 1 year, the deviations of OD2, Px, and Py were >10%; when stored at 4℃ for 1.5 years, the deviations of OD2, OD3, OD4, OD5, Py, and serum H / L were all >10.0%;

[0116] PIPES buffer: When stored at 4℃ for 1 year, the deviations of OD2, OD3, Px, Py, and serum H / L were >10%; when stored at 4℃ for 1.5 years, the deviations of OD2-OD5, Px, Py, and serum H / L were all >10.0%;

[0117] Acetate buffer: When stored at 4°C for 1 year, the deviations of OD2, OD3, OD4, Px, and Py were >10%; when stored at 4°C for 1.5 years, the deviations of OD2-OD5, Px, Py, and serum H / L were all >10.0%;

[0118] MOPS buffer: When stored at 4℃ for 1 year, the deviations of OD2-OD5, Px, Py, and serum H / L were less than 10%; when stored at 4℃ for 1.5 years, the deviations of OD2 and Py were both greater than 10.0%;

[0119] In summary, when HEPES buffer is used as the storage solution in R2, its OD2-OD5, Px, Py, and serum H / L can maintain a stable trend under various conditions, while when the other four buffers are used as storage solutions in R2, the above indicators have an upward or downward trend. HEPES buffer has the best stability as the storage solution for R2 reagents.

[0120] The inventors analyzed that the reason is that in reagent R2, the HEPES molecular structure contains acidic sulfonic acid groups and basic tertiary amine nitrogen, which is a zwitterionic buffer. The sulfonic acid group can give H + , the two tertiary amine nitrogens can accept H + The sulfonic acid group and the tertiary amine nitrogen in the aqueous solution can form a quaternary ammonium salt, so the sulfonic acid group and the tertiary amine nitrogen can act as a buffer pair for each other in the aqueous solution, and the tertiary amine and sulfonic acid groups in a single HEPES molecule can also transfer H + In aqueous solution, HEPES molecules, inner salts, and ions generated by sulfonic acid groups and tertiary amines are bonded to each other due to H + or OH - The transfer of the two can transform into each other to establish a balance relationship, and the movement of the balance relationship can resist the influence of external acids and bases to adjust the pH value of the solution to be stable.

[0121] Based on this characteristic of the HEPES buffer, the tertiary structure of the complement C1q antibody in the reagent R2 is ensured to be stable. By stabilizing the tertiary structure of the antibody protein, the complement C1q antibody binding site in the kit R2 of the present invention is more fully exposed, thereby ensuring the stability of the reagent and improving the titer of the antibody.

[0122] Example 5

[0123] In order to improve the linear range of reagent R2, the following experimental scheme was implemented, specifically:

[0124] Six different buffers (including HEPES buffer, PBS buffer, TRIS buffer, PIPES buffer, acetate buffer and MOPS buffer) were prepared to prepare six different R2 reagents, respectively, and the linear ranges of the six different R2 reagents were detected. The detection results are shown in Table 4 below;

[0125] Table 4

[0126]

[0127]

[0128]

[0129]

[0130]

[0131]

[0132] According to the expected values ​​and measured means in Table 4, the linear trend lines of 6 different R2 reagents are drawn, and the linear formula and linear correlation coefficient R of the linear trend line are given. 2 , the result is as follows Figure 1-6 As shown;

[0133] Depend on Figure 1-6 It can be seen that the upper limit of the linear range of HEPES buffer as R2 storage solution can reach above 70 mg / dL, and the linear correlation coefficient R 2 The linear correlation coefficient R 2 It is 0.98.

[0134] Example 6

[0135] In order to improve the accuracy of reagent R2, the following experimental scheme was implemented, specifically: two groups of R2 reagents with and without sodium chloride were prepared, and compared with the sample values ​​measured by the comparison method, and the accuracy of reagent R2 was evaluated based on the correlation coefficient and relative deviation. The test results are shown in Table 5 below;

[0136] Table 5

[0137]

[0138]

[0139] According to the measured data in Table 5, the measured values ​​of the two groups of R2 reagents with and without sodium chloride are plotted, and the linear trend lines of the sample values ​​measured by the comparison method are respectively plotted, and the linear formula and linear correlation coefficient R of the linear trend line are given. 2 , the result is as follows Figure 7 and Figure 8 As shown;

[0140] Depend on Figure 7 and Figure 8 It can be seen that after adding sodium chloride to R2 reagent, the relative deviation of the sample value is less than 10%, and the correlation coefficient R 2 >0.98, significantly better than the correlation coefficient R of R2 reagent without sodium chloride 2 ;

[0141] By adding sodium chloride to the buffer, the non-specific binding of low-affinity immune complexes in the serum to C1q can be prevented, that is, self-reaction can be avoided, thereby ensuring the accuracy of the complement C1q detection kit.

[0142] In the present invention, on the one hand, the inventors found that adding lipoprotein lipase (LPL) and bovine serum albumin (BSA) to reagent R1 can eliminate lipid blood interference, enhance the physical stability of sample detection, and ensure the stability of the sample and reagent reaction system. Interference may only occur when the blood lipid concentration is greater than 2000 mg / dL. At the same time, adding IgG-Fc fragments to reagent R1 avoids false positives caused by nonspecific binding of rheumatoid factors and complement C1q antibodies.

[0143] On the other hand, the inventors found that the type of buffer of reagent R2 can significantly affect the accuracy, linearity and stability of the kit. On this basis, the inventors screened the type of buffer of reagent R2. Among the six buffers of HEPES buffer, PBS buffer, TRIS buffer, PIPES buffer, acetate buffer and MOPS buffer, only HEPES buffer was used as the storage solution in R2. Its OD2-OD5, Px, Py and serum H / L can all maintain a stable trend. At the same time, the upper limit of its linear range can reach more than 70 mg / dL, and the linear correlation coefficient R2 reaches 0.99. In addition, the addition of sodium chloride to R2 can prevent the non-specific binding of low-affinity immune complexes in serum to C1q, that is, avoid self-reaction and ensure the accuracy of the complement C1q detection kit.

[0144] It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above and that the present invention can be implemented in other specific forms without departing from the spirit or essential features of the present invention. Therefore, the embodiments should be considered exemplary and non-restrictive in all respects, and the scope of the present invention is defined by the appended claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims be included in the present invention.

Claims

1. A complement C1q detection kit, characterized in that: The complement C1q detection kit comprises reagent R1 and reagent R2; The reagent R1 comprises: lipoprotein lipase, 2-3 KU / L, bovine serum albumin, 0.1-2 g / L, IgG-Fc fragment, 10-30 mg / L, diethylenetriaminepentaacetic acid, 0.2-0.8 g / L, sodium dihydrogen phosphate, 20-30 g / L, dipotassium hydrogen phosphate, 20-50 g / L, sodium chloride, 5-20 g / L, PEG-8000, 30-40 g / L, Tween-40, 0.2-1 g / L, and a pH value of 7.0-7.4; the solvent is purified water; Among them, lipoprotein lipase and bovine serum albumin work together to convert triglycerides in lipemia samples into colorless, water-soluble and non-antigenic glycerol and fatty acids, eliminating the interference of lipemia when the blood lipid concentration is less than 2000 mg / dL; The components and corresponding contents of the reagent R2 are: complement C1q antibody, 100-300 ml / L, 4-hydroxyethylpiperazineethanesulfonic acid, 100-300 mmol / L, sodium chloride, 5-20 g / L, sodium azide, 1 g / L, PEG-8000, 30-40 g / L, pH value is 7.0-7.4; the solvent is purified water; The preparation method of the complement C1q detection kit comprises the following steps: Preparation of reagent R1: dissolving a formulated amount of sodium dihydrogen phosphate in purified water, and then sequentially adding dipotassium hydrogen phosphate, diethylenetriaminepentaacetic acid and sodium chloride to obtain reagent R1 buffer; then, dissolving Tween and polyethylene glycol in the reagent R1 buffer in sequence, adjusting the pH value, and then adding bovine serum albumin, lipoprotein lipase and IgG-Fc fragment to obtain the reagent R1; Preparation of reagent R2: dissolve the formulated amount of 4-hydroxyethylpiperazineethanesulfonic acid in purified water, and then add sodium chloride, sodium azide and polyethylene glycol in sequence to obtain the reagent R2 storage solution; adjust the pH value, and then add complement C1q antibody, stir until completely dissolved, let stand at 2-8°C, and filter and sterilize to obtain the reagent R2.

2. A complement C1q detection kit according to claim 1, characterized in that: The reagent R1 comprises: lipoprotein lipase, 2.5 KU / L, bovine serum albumin, 0.5 g / L, IgG-Fc fragment, 20 mg / L, diethylenetriaminepentaacetic acid, 0.5 g / L, sodium dihydrogen phosphate, 27.0 g / L, dipotassium hydrogen phosphate, 28.6 g / L, sodium chloride, 9 g / L, PEG-8000, 35 g / L, Tween-40, 0.7 g / L, and a pH value of 7.0-7.4; the solvent is purified water; The ingredients and corresponding contents of the reagent R2 are: complement C1q antibody, 200 ml / L, 4-hydroxyethylpiperazineethanesulfonic acid, 200 mmol / L, sodium chloride, 15 g / L, sodium azide, 1 g / L, PEG-8000, 35 g / L, pH value is 7.0-7.4; the solvent is purified water.

3. A method for using the complement C1q detection kit as claimed in claim 1 or 2 in non-disease diagnosis, characterized in that: The complement C1q detection kit is used in conjunction with a biochemical analyzer, and the specific steps include: After the sample to be tested is mixed with reagent R1 and reagent R2 for reaction, the absorbance of the solution is detected, and the concentration of complement C1q in the sample to be tested is obtained according to the change in the absorbance.